Treatment of myelodysplastic syndromes with orally administered 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate.

1-beta-D-Arabinofuranosylcytosine-5'-stearylphosphate (fosteabine) was administered orally to patients with myelodysplastic syndromes (MDS); refractory anemia with excess of blasts (RAEB), RAEB in transformation, acute leukemia derived from RAEB and chronic myelomonocytic leukemia, in an early phase II study in a multi-institutional study. Among 62 evaluable patients, 2 patients achieved a complete remission, 6 a good response and 8 partial response by daily oral administration of 100-200 mg of fosteabine. The overall response rate was 25.8%. The response rates were almost the same among the four subtypes of MDS. Responses were reached 2-23 weeks (median, 8 weeks) after the start of therapy and continued for 3-50 weeks (median, 10 weeks). Major side effects were myelosuppression and gastrointestinal toxicities. In spite of the disadvantages, such as unpredictable absorption, this newly developed orally administrable cytarabine analogue will be a useful drug in the treatment of MDS.
AuthorsR Ohno, N Tatsumi, M Hirano, K Imai, H Mizoguchi, T Nakamura, M Kosaka, K Takatsuki, T Yamaya, K Toyama
JournalOncology (Oncology) Vol. 48 Issue 6 Pg. 451-5 ( 1991) ISSN: 0030-2414 [Print] SWITZERLAND
PMID1749580 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Arabinonucleotides
  • 1-arabinofuranosylcytosine-5'-stearylphosphate
  • Cytidine Monophosphate
  • Adult
  • Aged
  • Aged, 80 and over
  • Arabinonucleotides (adverse effects, therapeutic use)
  • Cytidine Monophosphate (adverse effects, analogs & derivatives, therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: